Search - tctmd.com

Displaying 161 - 174 of 174

Sort: Relevancy | Date

Presentation THT 2022

Moderator Led Discussion

Presenter: JoAnn Lindenfeld

February 01, 2022

Presentation THT 2022

Moderator Led Discussion

Presenter: Ulrich Jorde

February 01, 2022

Presentation THT 2022

Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

CON - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Presenter: Liviu Klein

February 01, 2022

Presentation THT 2022

PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Presenter: Roham Zamanian

February 01, 2022

Presentation THT 2022

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Alanna Morris

February 01, 2022

Presentation THT 2022

Should SGLT2 Inhibitors Be Started in the Hospital or in the Ambulatory Setting?

Presenter: Piotr Ponikowski

February 01, 2022

Presentation THT 2022

Right heart catheterization + Exercise testing – best practices for treatment selection in patients with PH due to Left Heart Disease

Presenter: Ryan Tedford

February 01, 2022

Presentation THT 2022

Timing of Intervention and the fate of the RV

Presenter: Barry Borlaug

February 01, 2022

Presentation THT 2022

Why should we do this?

Presenter: William Abraham

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors in HFrEF and HFpEF

Presenter: Stefan Anker

February 01, 2022

Conference THT 2023

THT 2023

March 20, 2023

March 22, 2023

Conference THT 2022

THT 2022

New York, NY

February 01, 2022

February 02, 2022

Advertisement

Moderator Led Discussion

Moderator Led Discussion

Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life

CON - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Should SGLT2 Inhibitors Be Started in the Hospital or in the Ambulatory Setting?

Right heart catheterization + Exercise testing – best practices for treatment selection in patients with PH due to Left Heart Disease

Timing of Intervention and the fate of the RV

Why should we do this?

SGLT2 Inhibitors in HFrEF and HFpEF

THT 2023

THT 2022

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content